Table 4.
Performance of Proclarix, PSAD, and the ERSPC MRI model for csPCa detection using the most sensitive threshold in biopsy-naïve men and men undergoing repeat biopsy
| Parameter | csPCs detection, n/N (%) |
|||||
|---|---|---|---|---|---|---|
| Proclarix (cutoff = 10%) |
PSAD (cutoff = 0.07 ng/ml/cm3) |
ERSPC MRI RC (cutoff = 1.5%) |
||||
| Initial Bx | Repeat Bx | Initial Bx | Repeat Bx | Initial Bx | Repeat Bx | |
| Sensitivity | 18/18 (100) | 7/7 (100) | 15/18 (83.3) | 6/7 (85.7 | 17/18 (94.4) | 7/7 (100) |
| Specificity | 30/103 (29.1) | 6/41 (14.6) | 33/103(32.0) | 8/41 (19.5) | 6/103 (5.8) | 5/41 (12.2) |
| Negative predictive value | 30/30 (100) | 6/6 (100 | 33/36 (91.7) | 8/9 (88.9) | 6/7 (85.7) | 5/5 (100) |
| Positive predictive value | 18/91 (19.8) | 7/42 (16.7) | 15/85 (17.6) | 6/39 (15.4) | 17/114 (14.9) | 7/43 (16.3) |
| Accuracy | 48/121 (39.7) | 13/48 (27.1) | 48/121(39.7) | 14/48 (29.2 | 23/121 (19.0) | 13/48 (27.1) |
| Prostate biopsies avoided | 30/121 (24.8) | 6/48 (12.5) | 36/121 (29.8) | 9/48 (18.8) | 7/121 (5.8) | 5/48 (10.4 |
| Decrease in iPCa overdetection | 7/121 (5.8) | 2/48 (4.2) | 7/121 (5.8) | 2/48 (4.2) | 1/121 (0.8) | 1/48 (2.1) |
| Misdiagnosis of csPCa | 0/18 (0) | 0/7 (0) | 3/18 (16.7) | 1/7 (14.3) | 1/8 (5.6) | 0/7 (0) |
PSAD = prostate-specific antigen density; PCa = prostate cancer; csPCa = clinically significant PCa; iPCa = insignificant PCa; Bx = biopsy; ESPRC = European Randomized Study of Screening for Prostate Cancer; MRI = magnetic resonance imaging; RC = risk calculator.